When protocols become overly complex, they can slam the brakes on study progress. But this kind of complexity does not arrive all at once.
It accumulates.
A biomarker is added in case it becomes important later. An extra imaging timepoint is included to capture more detail. A washout period is extended to avoid risk. A comorbidity exclusion is carried forward from a previous trial. Another patient-reported outcome instrument is layered in to strengthen the data package.
Each addition feels reasonable. Each has a defensible rationale.
Over time, however, this “just-in-case” approach can transform a focused study into an operational burden.
The cost of these decisions is rarely visible during early drafting. It shows up later, in delayed enrollment, higher screen failure rates, increased amendments, site fatigue, and frustrated patients.
The Additive Effect of Good Intentions
Clinical teams are trained to think defensively and rigorously. No one wants to miss a safety signal, overlook a meaningful endpoint, or lose optionality for future analysis.
But when every team optimizes for protection against uncertainty, protocols expand.
Additional procedures lengthen visits. More frequent assessments increase scheduling complexity. Narrow eligibility criteria shrink the recruitable population. Heavy documentation requirements add administrative load for sites.
None of these changes are catastrophic on their own. Together, they can materially alter feasibility.
Research from multiple industry analyses has shown that protocol complexity continues to increase across phases. Endpoints, procedures, and data points have steadily grown over the past decade. At the same time, amendment rates remain high, and enrollment timelines continue to strain budgets.
There is a connection.
The Downstream Consequences
When protocols are built with a “just-in-case” mindset, downstream effects compound:
Screening visits become longer and more resource-intensive.
Eligible patients are excluded for manageable conditions.
Sites must manage more data queries and procedural coordination.
Patients face increased travel, invasive procedures, or questionnaire fatigue.
Amendments are introduced when assumptions prove unrealistic.
Each amendment carries cost and delay. Each additional visit or test introduces friction.
In many cases, teams discover months into recruitment that certain eligibility criteria drastically reduce enrollment potential. Or that additional procedures discourage participation. By then, timelines are already under pressure.
The irony is that many of these protocol elements were introduced to reduce risk. Instead, they create new forms of operational risk.
Moving From Defensive to Deliberate
This does not mean removing rigor. It means applying discipline.
A deliberate protocol design process asks a few clear questions early:
What decision will this endpoint inform?
Is this procedure required to answer the primary scientific question?
How often does this assessment truly need to occur?
Does this exclusion criterion reflect current clinical practice?
What is the cumulative burden per patient and per site?
When teams quantify screening duration, visit time, blood volume, total number of assessments, and predicted eligibility rates, trade-offs become visible.
Real-world data can simulate how draft criteria perform against actual patient populations. Burden scoring frameworks can highlight which procedures disproportionately affect retention risk. Cross-functional review sessions can challenge legacy elements that persist without clear justification.
These conversations are most powerful before protocol lock.
Prevention Is More Efficient Than Rescue
Many sponsors invest heavily in rescue recruitment strategies when enrollment lags. Digital outreach, expanded site networks, and advertising campaigns can help, but they treat symptoms rather than root causes.
If eligibility is too narrow, outreach cannot create eligible patients. If visit schedules are unrealistic, marketing will not solve dropout.
Upstream discipline reduces the need for downstream rescue.
Trials designed with intentional, fit-for-purpose data collection and realistic eligibility criteria often experience:
These benefits compound across a development program.
A Cultural Shift
Reducing “just-in-case” design requires cultural change.
Teams must feel empowered to question inherited protocol elements. Governance processes must support thoughtful reduction rather than rewarding additive complexity. Leaders must recognize that simplicity can reflect strength, not compromise.
The goal is not minimalism. It is clarity.
Every protocol element should earn its place.
When design decisions are grounded in evidence, aligned with real-world practice, and evaluated for cumulative burden, clinical development moves faster and with greater confidence.
In an environment where timelines and budgets are under constant scrutiny, restraint may be one of the most strategic choices a team can make.
Continue the Conversation at SCOPE X
If you are exploring how AI, real-world data, and structured protocol intelligence can support more disciplined, fit-for-purpose trial design, join the discussion at SCOPE X, a focused event dedicated to AI innovation in clinical trials.
SCOPE X brings together clinical, operational, and data leaders to examine practical strategies for improving feasibility, reducing burden, and applying AI responsibly across the development lifecycle.